Mural Oncology To Host Virtual Investor Day, Provide New Clinical Insight Into Trial Design, Statistical Assumptions, And Progress Of Late-stage Trials Of Nemvaleukin
Mural Oncology To Host Virtual Investor Day, Provide New Clinical Insight Into Trial Design, Statistical Assumptions, And Progress Of Late-stage Trials Of Nemvaleukin
腫瘤學Oncology將舉辦虛擬投資者日,提供試驗設計、統計假設和Nemvaleukin後期試驗進展的新臨床見解
Key data readouts for the company's late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma.
公司的Nemvaleukin後期、潛在註冊試驗的關鍵數據讀數預計將於2025年第一季度末/第二季度初公佈,用於鉑金耐藥卵巢癌和2025年第二季度的粘膜黑色素瘤。
IND submission for Mural's IL-18 program planned for Q4 2025
Mural的IL-18項目的IND申請計劃於2025年第四季度
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。